Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Mineralys Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Mineralys Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each. Lorundrostat appears in 3 tracked Cross-Sector stories from March 12, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lorundrostat. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
FDA NDA Acceptance
FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
PDUFA Goal Date
Expected timeframe for the FDA's final decision on Lorundrostat commercialization.
Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
